Fredun Pharmaceuticals Limited has announced that its 39th Annual General Meeting (AGM) will be held on June 30, 2026. The meeting is scheduled to commence at 9:00 AM and will be conducted via video conference (VC) and other audio-visual means (OAVM). This format ensures compliance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI).

The company has filed the necessary disclosures with BSE Limited under Regulation 30 read with Schedule III Part A and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice regarding the AGM was published in Active Times (English) and Mumbai Lakshdeep (Marathi) on May 31, 2026, to inform the shareholders.

Meeting Details

The AGM will cover the business of the financial year ending March 31, 2026. Shareholders can participate remotely through the designated VC/OAVM platform provided by the company.

The filing was submitted by Fredun Medhora, Managing Director of Fredun Pharmaceuticals Limited.

Fredun Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026, on May 25, 2026. The company reported strong financial performance with substantial growth in revenue, profitability, and operating margins across both the full year and the fourth quarter. The Board of Directors recommended a final dividend of ₹0.70 per equity share and approved a 2:1 bonus issue, signaling confidence in future growth.

Financial Performance

For the fiscal year 2025-26, the company reported a standalone net profit of ₹33.21 crore, compared to ₹20.81 crore in the previous year. Total income from operations rose to ₹639.12 crore from ₹456.27 crore in the prior year. The fourth quarter also reflected robust year-on-year growth, with net profit climbing to ₹11.07 crore from ₹7.07 crore in the same period of the previous year. Quarterly revenue grew to ₹213.05 crore compared to ₹167.41 crore in the corresponding prior-year period.

Key Financial Metrics

The following table summarizes the standalone financial performance for the year ended March 31, 2026, alongside the quarterly comparison:

Operating Performance

The company's quarterly operating performance showed a marked improvement, with Q4 EBITDA rising to ₹29.13 crore from ₹17.44 crore in the same period of the previous year. The EBITDA margin expanded significantly to 13.67% from 10.42% year-on-year, reflecting improved operational efficiency and better cost management during the quarter.

Board Decisions

The Board of Directors recommended a final dividend of ₹0.70 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board approved the issuance of bonus shares to shareholders and warrant holders in the ratio of 2:1, meaning shareholders will receive two fully paid-up bonus equity shares of ₹10 each for every one existing equity share held. The record date for determining eligibility will be intimated in due course.

Corporate Actions

In other corporate decisions, the board approved an increase in the authorized share capital from ₹10 crore to ₹50 crore, subject to shareholder approval. The company also appointed M/s. Nikhil Maniar & Associates as Internal Auditor and M/s. Joshi Apte & Associates as Cost Auditor for the financial year 2026-2027. The statutory auditors issued an unmodified opinion on the standalone and consolidated financial results.